Laddar populära aktier...
Redeye makes minor revisions based on the Q2 report.
- We raise '24e-'26e adj. EBIT by 3-1% - Conducive conditions for organic growth - Trading at NTM EV...
- Strong momentum outside Sweden - We lower '24e-'25e EBITA by 2-1% - Share trading at 9x '24e EBITA...
- A sizeable margin improvement in both segments - EBITA estimates left largely unchanged - Trading ...
- Medicare expands lower-limb prosthetics coverage from 1 Sep - Good news for patients and Embla Med...
- EBITA SEK 245m (0% vs. ABGSCe, +2% vs. Modular Finance IR cons) - Company expects bigger vacation ...
Redeye strengthens its positive view of Vertiseit following a solid Q2 report, with 21% ARR growth a...
Redeye makes minor estimate revisions following Arise’s Q2 report, which was very much in line with ...
Redeye leaves an initial comment following the Q2 report published by Magle this morning.
Innofactor’s Q2 results fell below our expectations both due to a minor net sales decline and one-of...
Redeye was a bit surprised by the dip in gross margins in the second quarter.
- Sales and EBITDA in line with ABGSCe - Simplicity and predictability likely to drive limited cons.
Redeye see a Q2 report from Stille aligning with our estimates in terms of both sales and profitabil...
Redeye states that the Q2 report came in above its estimates on both sales and EBITDA.
- Sales -6% y-o-y, -12% vs. ABGSCe - EBIT of SEK 49m, +12% vs.
